Allergy Therapeutics plc (AIM: AGY), a biotechnology company that specialises in allergy vaccines, on Tuesday announced interim top-line results from the G306 Phase III trial of Grass MATA MPL, its subcutaneous allergen-specific immunotherapy for grass pollen-induced allergic rhinoconjunctivitis. The trial met its primary endpoint, showing a highly statistically significant reduction in Combined Symptom & Medication Score (CSMS) in the active treatment group compared to placebo (p≤0.0024).

The adaptive trial design allowed for an interim analysis, leading to the trial's early termination for success. Full analysis, including treatment effect data and secondary endpoint analysis, is expected in mid-December. The G306 trial, conducted in the US and Europe at 89 sites, demonstrated the efficacy and safety of Grass MATA MPL.

Preparations for the G308 paediatric study are underway to meet German regulatory requirements and an approved Paediatric Investigation Plan (PIP). Allergy Therapeutics focuses on the treatment and diagnosis of allergic disorders, with a broad product pipeline, including vaccines for grass, tree, house dust mite and peanut allergies.

Grass MATA MPL aims to address allergic rhinitis and rhinoconjunctivitis, offering a potential solution for seasonal and perennial allergies. The product uses an allergoid modified with glutaraldehyde and includes MPL as an adjuvant to enhance the immunogenic effect.